Amarin appeals ‘skinny label’ loss

Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net also tied to the original case after allegedly promoting use of the generic.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23 March 2023 Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

Generics

Hikma ‘skinny’ label does not infringe Amarin patents

6 January 2022 Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

Big Pharma

SCOTUS won’t resuscitate Amarin’s Vascepa patents

22 June 2021 Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Amarin appeals ‘skinny label’ loss

More on this story

Editor's picks

Editor's picks

More features